{"organizations": [], "uuid": "c5dbdd67fa2daa15044e7b0c937a137c89b2cd84", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-ultragenyx-fda/fda-approves-ultragenyxs-treatment-for-rare-type-of-rickets-idUSKBN1HO2NW", "country": "US", "domain_rank": 408, "title": "FDA approves Ultragenyx's treatment for rare type of rickets", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T20:04:00.000+03:00", "replies_count": 0, "uuid": "c5dbdd67fa2daa15044e7b0c937a137c89b2cd84"}, "author": "", "url": "https://www.reuters.com/article/us-ultragenyx-fda/fda-approves-ultragenyxs-treatment-for-rare-type-of-rickets-idUSKBN1HO2NW", "ord_in_thread": 0, "title": "FDA approves Ultragenyx's treatment for rare type of rickets", "locations": [], "entities": {"persons": [{"name": "ultragenyx", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "arun koyyur", "sentiment": "none"}], "locations": [{"name": "crysvita", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "ultragenyx", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "ultragenyx pharmaceutical inc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 17, 2018 / 5:08 PM / Updated 12 minutes ago FDA approves Ultragenyx's drug for rare form of rickets   \n(Reuters) -   has approved Ultragenyx Pharmaceutical Inc’s treatment for a rare and inherited form of rickets, a condition that causes weak bones, the agency said on Tuesday. \nCalifornia-based Ultragenyx’s shares rose 4.6 percent to $56.31 in afternoon trading. \nThe drug, Crysvita, was approved to treat x-linked hypophosphatemia in children and adults. \nThe condition causes bowed legs, short stature and bone pain in children, and affects about 3,000 children and 12,000 adults in the United States. \nSome adults with the disease experience joint pain, impaired mobility, tooth abscesses and hearing loss. \nThe FDA also gave Ultragenyx a “rare pediatric disease voucher,” which can be redeemed at a later date to receive a priority review from the agency for another product. Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur", "external_links": [], "published": "2018-04-17T20:04:00.000+03:00", "crawled": "2018-04-17T20:20:45.010+03:00", "highlightTitle": ""}